RxDoctor Payments Data

Robert Hancock, DPM

Podiatrist · Knoxville, TNNPI 1518975408

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.5% of the total across 33 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Smith+Nephew at 48.0% of the total. Reporting peaked in 2024 at $351 and has fallen 69.1% since, to $109 in 2025.

$1,174in general payments, 2019–2025

Across 33 payments — averaging $35.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$564
  • Organogenesis Inc.$276
  • Progenacare Global, LLC$80
  • Zyla Life Sciences, Inc.$65
  • Paratek Pharmaceuticals, Inc.$49
  • AbbVie$28
  • plus $113 from 6 others

What the payments were for

  • Food & beverage$1,10994%
  • Education$656%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Smith+Nephew16$564
Organogenesis Inc.4$276
Progenacare Global, LLC1$80
Zyla Life Sciences, Inc.1$65
Paratek Pharmaceuticals, Inc.3$49
AbbVie(2 entities)2$28
Medtronic1$27
Nevro Corp.1$25
Abbott1$18
Musculoskeletal Transplant Foundation Inc.1$15
Averitas Pharma Inc.1$13
Bioventus LLC1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,174 in reported general payments places this provider in the 60th percentile of 105 podiatrist providers in Tennessee.

See all podiatrist providers in Tennessee

Medicare billing

Part B allowed, 2024
$199,731
Medicare patients
440
Services billed
3,140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lidocaine-PrilocaineLidocaine/Prilocaine17$3,105
Mupirocin201$1,690
Celecoxib18$1,430
Cephalexin75$810
Ketoconazole21$678
Methylprednisolone100$557
Gabapentin54$533
Doxycycline Hyclate29$529
Terbinafine Hcl26$399
Meloxicam180$354
Ondansetron OdtOndansetron11$312
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav12$264
Allopurinol24$178
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen14$157

Paid to pharmacies, not to this prescriber.

Other podiatrist in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →